For research use only. Not for therapeutic Use.
Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC50 <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1[1][2].
| Catalog Number | I044407 |
| CAS Number | 1845777-61-8 |
| Synonyms | 2-chloro-N-[5-[3-[2-(dimethylamino)ethoxy]-4-oxopyrido[1,2-a]pyrimidin-7-yl]-2-methoxypyridin-3-yl]-4-fluorobenzenesulfonamide |
| Molecular Formula | C24H23ClFN5O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C24H23ClFN5O5S/c1-30(2)8-9-36-20-13-27-22-7-4-15(14-31(22)24(20)32)16-10-19(23(35-3)28-12-16)29-37(33,34)21-6-5-17(26)11-18(21)25/h4-7,10-14,29H,8-9H2,1-3H3 |
| InChIKey | BXKBZQAZYOZHJY-UHFFFAOYSA-N |
| SMILES | CN(C)CCOC1=CN=C2C=CC(=CN2C1=O)C3=CC(=C(N=C3)OC)NS(=O)(=O)C4=C(C=C(C=C4)F)Cl |
| Reference | [1]. WO2017101847 A1 [2]. International Nonproprietary Names for Pharmaceutical Substances (INN) |
